Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor
- PMID: 22926955
- PMCID: PMC4032368
- DOI: 10.1007/s10928-012-9267-z
Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor
Abstract
The target-mediated drug disposition (TMDD) model has been adopted to describe pharmacokinetics for two drugs competing for the same receptor. A rapid binding assumption introduces total receptor and total drug concentrations while free drug concentrations C (A) and C (B) are calculated from the equilibrium (Gaddum) equations. The Gaddum equations are polynomials in C (A) and C (B) of second degree that have explicit solutions involving complex numbers. The aim of this study was to develop numerical methods to solve the rapid binding TMDD model for two drugs competing for the same receptor that can be implemented in pharmacokinetic software. Algebra, calculus, and computer simulations were used to develop algorithms and investigate properties of solutions to the TMDD model with two drugs competitively binding to the same receptor. A general rapid binding approximation of the TMDD model for two drugs competing for the same receptor has been proposed. The explicit solutions to the equilibrium equations employ complex numbers, which cannot be easily solved by pharmacokinetic software. Numerical bisection algorithm and differential representation were developed to solve the system instead of obtaining an explicit solution. The numerical solutions were validated by MATLAB 7.2 solver for polynomial roots. The applicability of these algorithms was demonstrated by simulating concentration-time profiles resulting from exogenous and endogenous IgG competing for the neonatal Fc receptor (FcRn), and darbepoetin competing with endogenous erythropoietin for the erythropoietin receptor. These models were implemented in ADAPT 5 and Phoenix WinNonlin 6.0, respectively.
Figures
Comment in
-
Mechanism-Based Competitive Binding Model to Investigate the Effect of Neonatal Fc Receptor Binding Affinity on the Pharmacokinetic of Humanized Anti-VEGF Monoclonal IgG1 Antibody in Cynomolgus Monkey.AAPS J. 2016 Jul;18(4):948-59. doi: 10.1208/s12248-016-9911-4. Epub 2016 Apr 13. AAPS J. 2016. PMID: 27075465
Similar articles
-
Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model.J Pharmacokinet Pharmacodyn. 2009 Jun;36(3):199-219. doi: 10.1007/s10928-009-9118-8. Epub 2009 May 12. J Pharmacokinet Pharmacodyn. 2009. PMID: 19434483
-
Target mediated drug disposition with drug-drug interaction, Part II: competitive and uncompetitive cases.J Pharmacokinet Pharmacodyn. 2017 Feb;44(1):27-42. doi: 10.1007/s10928-016-9502-0. Epub 2017 Jan 10. J Pharmacokinet Pharmacodyn. 2017. PMID: 28074396 Free PMC article.
-
Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):803-12. doi: 10.1517/17425250902992901. Expert Opin Drug Metab Toxicol. 2009. PMID: 19505189 Review.
-
Approximations of the target-mediated drug disposition model and identifiability of model parameters.J Pharmacokinet Pharmacodyn. 2008 Oct;35(5):573-91. doi: 10.1007/s10928-008-9102-8. Epub 2008 Nov 13. J Pharmacokinet Pharmacodyn. 2008. PMID: 19005743
-
Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Minireview.J Clin Pharmacol. 2017 Feb;57(2):137-150. doi: 10.1002/jcph.804. Epub 2016 Sep 6. J Clin Pharmacol. 2017. PMID: 27489162 Review.
Cited by
-
Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors.J Pharmacokinet Pharmacodyn. 2020 Feb;47(1):5-18. doi: 10.1007/s10928-019-09663-2. Epub 2019 Nov 2. J Pharmacokinet Pharmacodyn. 2020. PMID: 31679083
-
A physiological model of granulopoiesis to predict clinical drug induced neutropenia from in vitro bone marrow studies: with application to a cell cycle inhibitor.J Pharmacokinet Pharmacodyn. 2020 Apr;47(2):163-182. doi: 10.1007/s10928-020-09680-6. Epub 2020 Mar 11. J Pharmacokinet Pharmacodyn. 2020. PMID: 32162138 Free PMC article.
-
Pharmacodynamic model for chemoradiotherapy-induced thrombocytopenia in mice.J Pharmacokinet Pharmacodyn. 2015 Dec;42(6):709-20. doi: 10.1007/s10928-015-9440-2. Epub 2015 Sep 4. J Pharmacokinet Pharmacodyn. 2015. PMID: 26341875
-
Algorithmic multiscale analysis for the FcRn mediated regulation of antibody PK in human.Sci Rep. 2022 Apr 13;12(1):6208. doi: 10.1038/s41598-022-09846-x. Sci Rep. 2022. PMID: 35418134 Free PMC article.
-
AFIR: A Dimensionless Potency Metric for Characterizing the Activity of Monoclonal Antibodies.CPT Pharmacometrics Syst Pharmacol. 2017 Apr;6(4):258-266. doi: 10.1002/psp4.12169. Epub 2017 Apr 4. CPT Pharmacometrics Syst Pharmacol. 2017. PMID: 28375563 Free PMC article.
References
-
- Levy G. Mechanism-based pharmacodynamic modeling. Clin Pharmacol Ther. 1994;56:356–358. - PubMed
-
- Mager DE. Target-mediated drug disposition and dynamics. Biochem Pharmacol. 2006;72:1–10. - PubMed
-
- Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med. 2006;354:2034–2045. - PubMed
-
- Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004;76:628–638. - PubMed
-
- Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715–725. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
